Introduction
been confirmed in multiple in vitro and in vivo studies [9] [10] [11] . Observed pharmacological effects of 72 moringa, linked to its anti-inflammatory, anti-bacterial, and antioxidant properties, are attributed to the 73 presence of phytoactive compounds such as flavonoids, phenolic acids, and, most notably, its unique 74 glucosinolates [12] . Moringa glucosinolates can be converted, via myrosinase, to highly bioactive and 75 stable moringa isothiocyanates (MICs) [9, 12] , of which MIC-1 (4-[(α-L-rhamnosyloxy)benzyl] 76 isothiocyanate) is the most abundant MIC in moringa seeds. Isothiocyanates from Brassicaceae plants, 77 taxonomically related to moringa, are well-known anti-inflammatory compounds that likely act via 78 activation of nuclear factor erythroid 2-related factor 2 (Nrf2), a key transcription factor involved in anti-79 inflammatory and antioxidant responses [13, 14] . Studies have shown that MIC-1 inhibited nuclear 80 factor-kappa B (NF-κB) expression and melanoma growth in nude mice [15] , and attenuated gene 81 expression of inducible nitric oxide synthase (iNOS) and interleukin-1β (IL-1β), as well as production of 82 nitric oxide (NO) and tumor necrosis factor-α/β (TNF-α/β) in RAW macrophages [12, 16 ]. An MIC-1-83 enriched moringa leaf extract also reduced IL-1β and TNF-α levels in plasma and various tissues, and 84 ameliorated weight gain, insulin resistance, and hepatic gluconeogenesis in obese mice [17] . 85
Furthermore, MIC-1 is known to activate NAD(P)H quinone oxidoreductase 1 (NQO1) [18] , one of the 86 phase II detoxifying enzymes that are directly regulated by Nrf2 [13] . Nrf2-deficient mice are susceptible 87 to UC and colorectal cancer, which was correlated with downregulation of antioxidant/phase II 88 detoxifying enzymes and upregulation of pro-inflammatory cytokines and related biomarkers [19] . 89 Therefore, Nrf2 signaling has been suggested to play a role in mediating the inflammatory response 90 involved in UC. 91
To examine the in vivo efficacy of potential therapeutic agents, various colitogenic substances, 92 such as dextran sulfate sodium (DSS), di-/tri-nitrobenzene sulfonic acid, oxazolone, or acetic acid, have 93 been used to establish chemically-induced UC models [20] . Of the experimental UC models, DSS-induced 94 8 Laboratories (Bar Harbor, ME) and acclimatized to the animal facility for 1 wk with ad libitum access to 132 drinking water and a rodent chow diet (Purina 5001; LabDiet, St. Louis, MO) prior to experiments. Mice 133 were initially housed 4 animals per cage, and maintained under standardized conditions (22 ± 2C, 12-h 134 light/dark cycle, and 50-60% humidity). Experiments began with mice at 8 wks of age, randomly assigned 135 to the experimental groups, because this age is optimal for successful and reproducible UC induction by 136 DSS [24] . For this study, two types of DSS-induced UC mouse models with features of acute and chronic 137 UC conditions were utilized. UC induction protocols and experimental designs for each UC model are 138 described below and summarized in Table 1 . 139
DSS-induced acute UC model

140
After acclimation, 32 mice were randomly divided into 4 experimental groups as follows based on their 141 body weights (n=8/group; 4 mice/cage): healthy control (water/vehicle), disease control (DSS/vehicle), 142 MSE treatment (DSS/MSE), or positive control (DSS/5-ASA). Acute UC was induced in mice (except 143 healthy control) by replacing their drinking water with autoclaved water containing freshly prepared 144 3.0% (w/v) DSS (ad libitum) for 5 d. Mice in healthy control were littermates that received autoclaved 145 water instead, and housed and processed identically during UC induction. Following UC induction, 146 treatments were administered daily to all mice via oral gavage in a volume of 5 ml/kg body weight (bw) 147 with animal feeding needles (20G x 1.2"; Cadence, Inc., Staunton, VA) for 7 consecutive d. Treatments 148 included vehicle (autoclaved water), 150 mg/kg bw of MSE, or 50 mg/kg bw of 5-ASA. Mice were 149 allowed free access to autoclaved drinking water and chow pellets during the time. 150
DSS-induced chronic UC model
151
After acclimation, 24 mice were assigned to 4 weight-balanced experimental groups (n=6/group; 3 152 mice/cage) as described above. Chronic UC was induced in mice by 4 cycles of 2.5% (w/v) DSS in drinking 153 water for 3 d, which was alternated with 6 d of autoclaved water (ad libitum) in between, resulting in a 154 total of 30 d for the entire induction period. Subsequently, treatments (vehicle, MSE, or 5-ASA) were9 orally delivered to mice daily for 14 consecutive d, and mice had free access to autoclaved water and 156 chow during the time. 157 158 
Disease activity index (DAI) assessment
167
DAI was scored following the criteria described in Table 2 in order to validate the progression of UC in 168 both models. The DAI score was calculated as a sum of the scores for % bw change, intestinal bleeding, 169 stool consistency, and rectal prolapse. % bw change was calculated as: [(bw each d -initial bw) / initial 170 bw] x 100. To score intestinal bleeding, bloody stool was confirmed by either visible observation or the 171 fecal occult bleeding test (FOBT) using a commercially available kit (Sure-Vue™; Thermo Fisher Scientific, Tissue isolation, measurements, and preparations
178
At the time of sacrifice in acute and chronic UC experiments, the spleen and colon were dissected from 179 each mouse and measured within 5-10 min postmortem. Individual spleen tissues were weighed (mg). 180
The colons, connected to the cecum, were isolated by separating them from the ileocecal junction of the 181 small intestine and the distal rectum of the anus, and thoroughly flushed with cold PBS (pH 7.4; 182 supplemented with 1% antibiotics) using a ball tip dosing needle attached to a 10 ml syringe to remove 183 feces and blood. After pushing out remaining colon contents with a blunt forceps, the colons were 184 straightened and measured in length (cm). The colons were then separated from cecum and weighed. 185 Subsequent to these measurements, the colons were opened by longitudinal incision, and washed three 186 times in cold PBS (pH 7.4; supplemented with 1% antibiotics) for a complete removal of fecal matter, 187 from which only middle-to-distal colon segments were used for further analyses. These colon segments 188 were further cut into 3 pieces longitudinally, each of which was individually processed for organ culture, 189 quantification of gene expression, and histopathological assessments. using the histopathological scoring system with total score range from 0 to 11 (Table 3) 
Quantification of colonic pro-inflammatory biomarkers
222
From the supernatant of ex vivo colon cultures, pro-inflammatory chemokine, keratinocyte-derived 223 chemokine (KC), and pro-inflammatory cytokine, TNF-α, were quantified using the mouse CXCL1/KC 224 DuoSet ELISA kit and the mouse TNF-α Quantikine ELISA kit, respectively. Myeloperoxidase (MPO), a 225 marker for neutrophil infiltration in colonic epithelial tissues, was also measured using the mouse MPO 226 DuoSet ELISA kit. All ELISA kits were purchased from R&D Systems, Inc. (Minneapolis, MN), and utilized 227 according to manufacturer's protocols. NO production was analyzed in duplicates using the Griess 228 Reagent System (Promega Corp., Madison, WI) following the manufacturer's protocol. Nitrite levels 229 (µM) in individual samples were determined at 520 nm by comparison with a standard curve of nitrite 230 (0.1 M NaNO2; 0 to 100 µM). Throughout these analyses, absorbance was read using a Synergy HT™ 231 microplate reader (BioTek Instruments, Inc., Winooski, VT), and individual concentrations obtained from 232 each colon sample were normalized by the measured colon tissue weight (g). 
Results
285
MSE alleviates UC symptoms
286
No animals died during acute or chronic UC periods. DAI score was calculated by combining scores of the 287 following parameters: % bw change, intestinal bleeding, stool consistency, and rectal prolapse (see 288 Table 2 ). Rectal prolapse was not observed in mice tested in either UC phase. Generally, mice receiving 289 DSS manifested similar clinical symptoms seen in human UC, such as severe bw loss, diarrhea, and 290 intestinal bleeding. By the end of UC induction, gradual increases of DAI scores were observed in acute 291 (~7.75 times increase at d 5 induction) and chronic (~5.55 times increase at d 30 induction) UC models 292 compared to healthy control (Fig 1A and 1B) . Table 1 and DAI scoring criteria in Table 2 . Data 308 are expressed as mean ± SEM. 
B
water, reflecting the relapse-remission pattern of UC symptoms (Fig 1B) . In acute UC, both MSE and 5-314 ASA significantly decreased DAI scores compared to disease control for 6 consecutive d with a decrease 315 starting from d 1 (-29.2% by MSE; -47.6% by 5-ASA) (Fig 1A) . At d 7, however, no significant differences 316 were found in DAI scores among any experimental groups, possibly due to a partial natural recovery 317 from DSS-induced UC (Fig 1A) . In chronic UC, MSE showed a strong trend towards reducing clinical 318 symptoms compared to disease control starting from d 2 (-73.3%). The remission persisted throughout 319 the treatment. At the end of treatment (d 14), the DAI score dropped almost to that of the healthy 320 control (-93%) (Fig 1B) . While 5-ASA and MSE showed similar trends in relieving UC symptoms, the 5-321
ASA effect was only significant at d 2 (Fig 1B) , while the MSE effect was significant at d 2, 10, 12 and 14 322 (Fig 1B) . 323
324
MSE restores colon integrity in DSS-induced UC models
325
Bw loss, rectal bleeding, and inflammation exerted during UC are associated with colon shortening and 326 spleen enlargement [24, 28] . In this study, spleen weights were not affected by either DSS or treatments 327 (MSE or 5-ASA) in both acute and chronic UC mice (Fig 2A) . cm vs. 7.5 ± 0.2 cm for acute UC; 6.3 ± 0.4 cm vs. 7.6 ± 0.4 cm for chronic UC). MSE showed a positive 348 trend in reversing colon shortening (6.9 ± 0.1 cm for acute UC, not significant at p<0.05; and 7.3 ± 0.3 cm 349 for chronic UC). 5-ASA did not recover colon shortening in either model (6.4 ± 0.3 cm for acute UC; 6.6 ± 350 0.2 cm for chronic UC) (Fig 2B) . The colon weight/length ratio, an indicator of UC-associated colonic 351 edema and inflammation [29] , was significantly higher in disease control (49.5 ± 3.1 for acute UC; 48.7 ± 352 2.1 for chronic UC) and following 5-ASA treatment (48.7 ± 2.1 for acute UC; 55.9 ± 5.2 for chronic UC) 353 compared to healthy control (34.9 ± 2.1 for acute UC; 39.5 ± 0.9 for chronic UC). MSE treatment reduced 354 the ratio compared to disease control in both UC models (41.9 ± 2.7 for acute UC, not significant at 355 p<0.05; and 41.5 ± 1.0 for chronic UC) (Fig 2C) . 356
357
MSE moderately lessens histopathologies associated with DSS-
358
induced UC
359
The histopathological analysis was performed in H&E-stained distal colon sections of mice with DSS-360 induced acute and chronic UC. Microscopic images (20x magnification) of representative colonic 361 sections were taken for each group, and histopathological scores were assessed (Table 3 ). In both UC 362 models, the healthy control groups showed intact epithelium with undamaged crypts and no ulcerative 363 foci (Fig 3A and 3B) . observations of H&E-stained colonic sections of (A) acute UC mice (n=8/group), and (B) chronic UC mice 382 (n=6/group). Experimental designs and disease induction procedures are defined in Table 1 .
(C) 383
Associated colonic histopathological scores calculated as sum of scores of each parameter consisting of 384 histopathological scoring system as described in Table 3 . Histological images were acquired by 20x 385 magnification (Scale bar = 50 m). Data are expressed as mean ± SEM. Different letters indicate 386 significant differences between groups (p<0.05). 5-aminosalicylic acid (5-ASA); dextran sulfate sodium 387 (DSS); hematoxylin and eosin (H&E); moringa seed extract (MSE); ulcerative colitis (UC). 388 reported in the DSS-induced UC model. Extensive erosion and submucosal edema were also presented 391 in the distal colon as the indication of an inflammatory phenotype in this group (Fig 3A and 3B) . On the 392 contrary, treatment with either MSE or 5-ASA resulted in less severe inflammation (relatively less 393 extensive epithelial erosion) and development of a few regenerating foci compared to disease control in 394 acute UC (Fig 3A) . In chronic UC, neither MSE nor 5-ASA treatments measurably rescued chronic 395 inflammation, as extensive mucosal damage and confluent ulcerative erosion were similarly observed in 396 treated and disease control groups (Fig 3B) . In the assessment of histopathological scores, all mice in 397 DSS-treated groups showed a marked increase of the scores, which was significantly reduced by 5-ASA. 398 MSE showed a trend in reducing histopathological scores in acute UC, which was not significant at 399 p<0.05 (Fig 3C) . were decreased by MSE (not significantly at p<0.05), whereas 5-ASA significantly decreased levels of KC 406 (-48.1%) and NO (-27.4%) (Fig 4A-4C) . acute UC (n=8/group) and chronic UC (n=6/group) mice. All concentrations were normalized to 1 g of 418 the colon tissue weight. Fecal levels of (E) Lcn-2 were normalized to 1 g of the fecal weight. 419
Experimental designs and disease induction procedures are defined in Table 1 The levels of MPO were significantly lowered by both MSE (-35.7%) and 5-ASA (-57.0%) in the acute UC 426 model (Fig 4D) . In chronic UC, reductions in these markers were more obvious, showing that, compared 427 to disease control, colonic productions of all tested pro-inflammatory markers were significantly 428 lowered by MSE (-2.3% for KC; -26.4% for TNF-α; -41.8% for NO; -67.1% for MPO). The effect of 5-ASA 429 was negligible in chronic UC, only showing a significant reduction in MPO (-51.9%) (Fig 4A-4D) . Mice 430 receiving DSS showed a dramatic increase of the fecal Lcn-2 level in both acute and chronic UC, which, in 431 acute UC, was significantly reduced by MSE (-7.7%), but not by 5-ASA, compared to disease control (Fig  432   4E) . 433
434
MSE downregulates colonic expression of pro-inflammatory cytokines
and iNOS
436
Pathological process of UC is closely related to the increased level of pro-inflammatory cytokines that 437 can also activate iNOS. We examined the effect of MSE on colonic expression of pro-inflammatory 438 cytokines including IL-1β, IL-6, and TNF-α, as well as iNOS. In acute UC, compared to healthy control, all 439 these pro-inflammatory marker genes were upregulated by DSS (up to ~150 times for iNOS). However, 440 in the acute model, the expression of these pro-inflammatory marker genes was, in most cases, 441 markedly lowered by MSE (-73.2% for IL-1β; -97.1% for IL-6; -43.4% for TNF-α, not significant at p<0.05; -442 73.2% for iNOS) compared to disease control (Fig 5A-5D) . 
Fig 5. Effects of MSE on colonic expression of pro-inflammatory markers, tight-junction proteins, and 451
Nrf2-mediated enzymes in DSS-induced UC. Gene expression of (A) IL-1β, (B) IL-6, (C) TNF-α, (D) iNOS, 452
(E) claudin-1, (F) ZO-1, (G) GSTP1, (H) NQO1, and (I) HO1 was analyzed by qPCR in colon tissues of acute 453 UC (n=8/group) and chronic UC (n=6/group) mice. All data are expressed as a relative fold change 454 compared to healthy control (value = 1.0). Experimental designs and disease induction procedures are 455 defined in Table 1 . Data are expressed as mean ± SEM. Different letters indicate significant differences 456 between groups (p<0.05). 5-aminosalicylic acid (5-ASA); dextran sulfate sodium (DSS); glyceraldehyde-3-457 phosphate dehydrogenase (GAPDH); glutathione-S-transferase pi 1 (GSTP1); hydroxymethylbilane 458 synthase (HMBS); heme oxygenase 1 (HO1); interleukin-1β (IL-1β); interleukin-6 (IL-6); inducible nitric 459 oxide synthase (iNOS); moringa seed extract (MSE); NAD(P)H quinone oxidoreductase 1 (NQO1); tumor 460 necrosis factor-α (TNF-α); ulcerative colitis (UC), zonula occludens-1 (ZO-1). 461 462 5-ASA, similar to MSE, downregulated the expression of the pro-inflammatory genes, except for TNF-α 463 (Fig 5A-5D) . In chronic UC, neither MSE nor 5-ASA showed significant effects on pro-inflammatory 464 marker genes (Fig 5A-5D) . expression; however, MSE increased claudin-1 expression in both UC models and the effect was highly 471 significant in the acute model (558%) (Fig 5E) . A similar result was observed for ZO-1, showing decreased 472 gene expression by DSS, which was upregulated by MSE, but not by 5-ASA, in acute (148%; not27 significant at p<0.05) and chronic UC (148%) compared to disease control (Fig 5F) . Gene expression of 474 phase II detoxifying enzymes, including GSTP1, NQO1, and HO1, are directly regulated by the Nrf2 475 transcription factor. Nrf2 can also modulate NF-κB-dependent pro-inflammatory signals [19] . In chronic 476 UC, MSE led to upregulated gene expression of GSTP1 (160%), NQO1 (144%), and HO1 (128%), 477 compared to disease control; however, only GSTP1 upregulation was significant (Fig 5G-5I) . In addition, 478 the expression of NQO1 and HO1 genes was significantly upregulated by MSE compared to healthy 479 control (Fig 5H and 5I) . In acute UC, DSS showed a trend towards reducing the Nrf2-regulated gene 480 expression that was not affected by MSE or 5-ASA (Fig 5G-5I) . Acute UC is characterized by rapid onset of severe clinical symptoms within a relatively short 488 induction period, whereas chronic UC represents less severe and more sustained inflammation 489 developed through a slower but long-lasting induction period with possible flare-up and remission 490 symptomatic cycles. DSS disrupts the integrity of the mucosal barriers [20] , leading to increased 491 permeability of luminal toxic substances into the lamina propria and submucosal compartments, 492 resulting in secondary inflammation in the intestine [24] . In our study, two DSS-induced UC models were 493 successfully established, with more severe UC symptoms observed in the acute than chronic UC model, 494 reflected by higher DAI scores (~7x vs. ~5x higher DAI score in acute vs. chronic UC, respectively) 495 compared to DSS-untreated mice. Oral delivery of MSE (150 mg/kg bw for 1 or 2 wks) promptly reduced 496 the severity of UC symptoms in both UC models, including improvements in bw loss, stool consistency, 497 and intestinal bleeding. MSE improved the integrity of colon tissues by correcting colon shortening, 498 likely due to loss in crypt structure, and colon thickness, which is due to edema formation [30] . MSE also 499 reduced the severity of colonic inflammation developed during UC, diminished epithelial erosion and 500 regenerated a few foci in colonic tissues in acute UC. However, MSE failed to attenuate these 501 histopathological signs of UC in the chronic UC model. This is, nevertheless, consistent with a previous 502 report that complete healing of bowel ulceration may not be concomitant with clinical remission of UC 503 symptoms, and with recommendations from previous clinical studies to measure mucosal restitution 504 after 8 wks of treatments [31] . 5-ASA, an anti-inflammatory drug for treatment of mild-to-moderateseverity of UC in humans, was used as a positive control with a recommended dose of 50 mg/kg bw [31] . 506 5-ASA produced a comparable DAI score to that of MSE in acute UC, but was less efficacious than MSE in 507 chronic UC. Moreover, the impact of 5-ASA on colonic histopathological signs of UC was only evident in 508 acute UC, and could not improve aberrant characteristics of colon tissues, like colon shortening, caused 509 by DSS. Our observations in chronic UC mice corroborate previous findings that 5-ASA, albeit widely 510 used as a first-line therapy for UC, is largely ineffective in chronic UC [32] . and increased pro-inflammatory cytokines (TNF-α, IL-6, IL-17, IL-12, and IFN-γ) is described in IBD 538 patients [45] . We also observed increased production and/or gene expression of pro-inflammatory 539 markers (IL-1, IL-6, TNF-α, iNOS, NO, KC, MPO, and Lcn-2) in both UC models. MSE treatment generally 540 reduced these markers, although the effect of MSE differed in acute and chronic UC models. Similarly, a 541 previous study showed that PEITC downregulated colonic IL-1β gene expression in DSS-induced UC mice 542
[25]. These results are consistent with the well-documented anti-inflammatory effects of various 543 isothiocyanates, which are mediated, at least in part, by Nrf2 activation [45] . 544
Tight-junction proteins, such as ZO-1, occludins, and claudins, form physiologically active 545 barriers in intestinal epithelial cells that can be disrupted in IBD [29, 46, 47] . For example, the loss of ZO-546 1 protein was observed in DSS-induced UC mice [29] . Our data showed that, while DSS treatment led to 547 some downregulation of claudin-1 and ZO-1 genes, MSE restored or upregulated these genes, consistent 548 with its observed therapeutic effects in UC. 549
Oxidative stress is both a consequence of UC [48] and one of its contributing factors [49] . Our 550 data suggest that MSE protects against chronic colonic inflammation by lowering oxidative stress 551 through upregulation of antioxidant/phase II detoxifying enzymes, in particular, GSTP1. GSTP1 is thexenobiotics to glutathione [50] , and DSS-induced UC mice exhibited downregulation of GST gene 554 expression [50] . We suggest that the upregulation of antioxidant enzymes observed in our study is the 555 result of MIC-1-mediated activation of Nrf2, similar to that caused by sulforaphane in DSS-induced UC 556 [14] . Studies have shown that isothiocyanates such as sulforaphane and PEITC activate Nrf2, which 557 subsequently reduces oxidative stress and inflammation [13, 51] . Nrf2 knockout attenuated the anti-558 inflammatory effects of PEITC and curcumin in macrophages ex vivo [52] . Therefore, MIC-1 and other 559 isothiocyanates are likely responsible for interactions with the Nrf2/Keap1 complex and further 560 downstream processes [53] . 561
In conclusion, MSE, enriched with the MIC-1, its main bioactive, ameliorated pathological events 562 associated with acute and chronic UC. Anti-inflammatory and antioxidant activities of MSE are likely 563 associated with Nrf2-mediated anti-inflammatory/antioxidant signaling pathway. This study supports 564 the therapeutic potential of MSE for prevention and treatment of UC and should be further explored in 565 human studies. 566 567
